Catherine Chunda Liyoka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Catherine Chunda Liyoka has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Alex Osei-Akoto
Kumasi Ashanti Region Kwame Nkrumah University of Science and Technology
2 shared publications- Alexis A. Thompson
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
2 shared publications Charles Kiyaga
Central Public Health Laboratories, Kampala, Uganda
2 shared publications- Daniel Ansong
Kumasi Ashanti Region Kwame Nkrumah University of Science and Technology
2 shared publications - Elizabeth Mkutumula
Blantyre Southern Region Malawi-Liverpool-Wellcome Trust Clinical Research Programme
2 shared publications Emmanuela E. Ambrose
Haematology Section, Paediatric Department, Bugando Medical Centre, Mwanza, Tanzania
2 shared publications
Latest Publications
- Open Access
- 6 August 2026
- Published by National Institute for Health and Care Research in NIHR Open Research
- Vol. 6, 30
Introducing a safeguarding culture in research institutions: a multi-national partnership
Background Research projects have a responsibility to safeguard their staff and research participants by treating them with respect and dignity and protecting them from harm. This is especially important in international development partnerships where substantial imbalances in power relations, resources and research governance structures are common. Demands for evidence and sharing of good practice about how international research partnerships can enhance safeguarding cultures in partners’ institutions are increasing. However, these partnerships are missing opportunities to amplify their projects’ impact beyond the project team and research focus. Methods Our multi-national implementation research partnership is focused on patient-centred care for sickle cell disease in Africa and involves participatory approaches with community members and vulnerable patients. After establishing a project safeguarding plan and training, partners were keen to extend a safeguarding culture to their own institutions. We describe how our safeguarding trainers tailored the project’s approach and resources to introduce the concept of safeguarding in their institutions and set up training in four diverse contexts in Ghana, Nigeria and Zambia. Results Lessons to apply to other research partnerships have been synthesised by comparing common factors which helped and hindered their efforts. These included jointly developing tools to identify safeguarding risks, using the projects’ establishing safeguarding processes, flexibility in the use of training resources, supporting institutionally influential safeguarding trainers, engaging institutional leaders as safeguarding advocates, embedding safeguarding within institutional systems, and planning for sustainability. Conclusion Influencing institutional culture change to embed safeguarding approaches is a long process and is unlikely to be achieved within the lifetime of a short-term project. However, with careful planning and encouragement from research funders, the activities and resources within a research partnership can go well beyond simply delivering the primary research outputs. Even within 2–3 years they can be used to lever substantial impact on the safeguarding culture in partners’ institutions.
- 6 August 2026
- Published by National Institute for Health and Care Research in NIHR Open Research
- Vol. 6, 30
Open AccessIntroducing a safeguarding culture in research institutions: a multi-national partnership
Background Research projects have a responsibility to safeguard their staff and research participants by treating them with respect and dignity and protecting them from harm. This is especially important in international development partnerships where substantial imbalances in power relations, resources and research governance structures are common. Demands for evidence and sharing of good practice about how international research partnerships can enhance safeguarding cultures in partners’ institutions are increasing. However, these partnerships are missing opportunities to amplify their projects’ impact beyond the project team and research focus. Methods Our multi-national implementation research partnership is focused on patient-centred care for sickle cell disease in Africa and involves participatory approaches with community members and vulnerable patients. After establishing a project safeguarding plan and training, partners were keen to extend a safeguarding culture to their own institutions. We describe how our safeguarding trainers tailored the project’s approach and resources to introduce the concept of safeguarding in their institutions and set up training in four diverse contexts in Ghana, Nigeria and Zambia. Results Lessons to apply to other research partnerships have been synthesised by comparing common factors which helped and hindered their efforts. These included jointly developing tools to identify safeguarding risks, using the projects’ establishing safeguarding processes, flexibility in the use of training resources, supporting institutionally influential safeguarding trainers, engaging institutional leaders as safeguarding advocates, embedding safeguarding within institutional systems, and planning for sustainability. Conclusion Influencing institutional culture change to embed safeguarding approaches is a long process and is unlikely to be achieved within the lifetime of a short-term project. However, with careful planning and encouragement from research funders, the activities and resources within a research partnership can go well beyond simply delivering the primary research outputs. Even within 2–3 years they can be used to lever substantial impact on the safeguarding culture in partners’ institutions.
- Open Access
- 1 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (9) , 3200-3206
Newborn screening results for sickle cell disease from the ASH Consortium on Newborn Screening in Africa (CONSA)
The Consortium on Newborn Screening in Africa (CONSA), launched by the American Society of Hematology in 2020, is designed to initiate and expand sustainable newborn screening (NBS) programs for sickle cell disease (SCD) across sub-Saharan Africa. This multiyear pilot program includes 11 clinical sites in 7 countries, namely Ghana, Kenya, Liberia, Nigeria, Tanzania, Uganda, and Zambia. After extensive training of laboratory and clinical personnel, dried blood spots were collected from newborns and tested by isoelectric focusing at central laboratories within each country. Positive samples were confirmed, and the affected infants were invited into clinical care for penicillin prophylaxis, malaria prevention, routine immunizations, and family education. As of November 2025, almost 175 000 samples have been collected and assessed. The overall prevalence of SCD was 1.46%, with the highest prevalence in Mwanza, Tanzania (2.00%). The majority of positive screening results were homozygous HbSS (81.5%), along with compound heterozygous HbSC (11.0%) and HbSβ+ thalassemia (7.5%). Hemoglobin S trait was common throughout the countries with an average of 16.17%, whereas hemoglobin C trait had an incidence of 1.59% and was found primarily in Ghana and Nigeria. Additional hemoglobin variants were also detected in several countries. Confirmatory samples have been documented in about one-third of infants with a positive screening result, with 87.8% of those confirmed to have SCD. Fewer than half of the affected infants have documented clinical follow-up at CONSA sites for various logistical and financial reasons. CONSA has made great strides in promoting NBS for SCD in sub-Saharan Africa, but gaps in the confirmatory testing and enrollment into clinical care persist.
- 1 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (9) , 3200-3206
Open AccessNewborn screening results for sickle cell disease from the ASH Consortium on Newborn Screening in Africa (CONSA)
The Consortium on Newborn Screening in Africa (CONSA), launched by the American Society of Hematology in 2020, is designed to initiate and expand sustainable newborn screening (NBS) programs for sickle cell disease (SCD) across sub-Saharan Africa. This multiyear pilot program includes 11 clinical sites in 7 countries, namely Ghana, Kenya, Liberia, Nigeria, Tanzania, Uganda, and Zambia. After extensive training of laboratory and clinical personnel, dried blood spots were collected from newborns and tested by isoelectric focusing at central laboratories within each country. Positive samples were confirmed, and the affected infants were invited into clinical care for penicillin prophylaxis, malaria prevention, routine immunizations, and family education. As of November 2025, almost 175 000 samples have been collected and assessed. The overall prevalence of SCD was 1.46%, with the highest prevalence in Mwanza, Tanzania (2.00%). The majority of positive screening results were homozygous HbSS (81.5%), along with compound heterozygous HbSC (11.0%) and HbSβ+ thalassemia (7.5%). Hemoglobin S trait was common throughout the countries with an average of 16.17%, whereas hemoglobin C trait had an incidence of 1.59% and was found primarily in Ghana and Nigeria. Additional hemoglobin variants were also detected in several countries. Confirmatory samples have been documented in about one-third of infants with a positive screening result, with 87.8% of those confirmed to have SCD. Fewer than half of the affected infants have documented clinical follow-up at CONSA sites for various logistical and financial reasons. CONSA has made great strides in promoting NBS for SCD in sub-Saharan Africa, but gaps in the confirmatory testing and enrollment into clinical care persist.
- Open Access
- 24 April 2026
- Published by National Institute for Health and Care Research in NIHR Open Research
- Vol. 6, 30
Embedding a safeguarding culture in research institutions: a multi-national partnership
Background Research projects have a responsibility to safeguard their staff and research participants by treating them with respect and dignity and protecting them from harm. This is especially important in international development partnerships where substantial imbalances in power relations, resources and research governance structures are common. Demands for evidence and sharing of good practice about how international research partnerships can enhance safeguarding cultures in partners’ institutions are increasing. However, these partnerships are missing opportunities to amplify their projects’ impact beyond the project team and research focus. Methods Our multi-national implementation research partnership is focused on patient-centred care for sickle cell disease in Africa and involves participatory approaches with community members and vulnerable patients. After establishing a project safeguarding plan and training, partners were keen to extend a safeguarding culture to their own institutions. We describe how our safeguarding trainers tailored the project’s approach and resources to introduce the concept of safeguarding in their institutions and set up training in four diverse contexts in Ghana, Nigeria and Zambia. Results Lessons to apply to other research partnerships have been synthesised by comparing common factors which helped and hindered their efforts. These included jointly developing tools to identify safeguarding risks, using the projects’ establishing safeguarding processes, flexibility in the use of training resources, supporting institutionally influential safeguarding trainers, engaging institutional leaders as safeguarding advocates, embedding safeguarding within institutional systems, and planning for sustainability. Conclusion Influencing institutional culture change to embed safeguarding approaches is a long process and is unlikely to be achieved within the lifetime of a short-term project. However, with careful planning and encouragement from research funders, the activities and resources within a research partnership can go well beyond simply delivering the primary research outputs. Even within 2–3 years they can be used to lever substantial impact on the safeguarding culture in partners’ institutions.
- 24 April 2026
- Published by National Institute for Health and Care Research in NIHR Open Research
- Vol. 6, 30
Open AccessEmbedding a safeguarding culture in research institutions: a multi-national partnership
Background Research projects have a responsibility to safeguard their staff and research participants by treating them with respect and dignity and protecting them from harm. This is especially important in international development partnerships where substantial imbalances in power relations, resources and research governance structures are common. Demands for evidence and sharing of good practice about how international research partnerships can enhance safeguarding cultures in partners’ institutions are increasing. However, these partnerships are missing opportunities to amplify their projects’ impact beyond the project team and research focus. Methods Our multi-national implementation research partnership is focused on patient-centred care for sickle cell disease in Africa and involves participatory approaches with community members and vulnerable patients. After establishing a project safeguarding plan and training, partners were keen to extend a safeguarding culture to their own institutions. We describe how our safeguarding trainers tailored the project’s approach and resources to introduce the concept of safeguarding in their institutions and set up training in four diverse contexts in Ghana, Nigeria and Zambia. Results Lessons to apply to other research partnerships have been synthesised by comparing common factors which helped and hindered their efforts. These included jointly developing tools to identify safeguarding risks, using the projects’ establishing safeguarding processes, flexibility in the use of training resources, supporting institutionally influential safeguarding trainers, engaging institutional leaders as safeguarding advocates, embedding safeguarding within institutional systems, and planning for sustainability. Conclusion Influencing institutional culture change to embed safeguarding approaches is a long process and is unlikely to be achieved within the lifetime of a short-term project. However, with careful planning and encouragement from research funders, the activities and resources within a research partnership can go well beyond simply delivering the primary research outputs. Even within 2–3 years they can be used to lever substantial impact on the safeguarding culture in partners’ institutions.
- Open Access
- 27 October 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (24) , 6187-6197
The Consortium on Newborn Screening in Africa for sickle cell disease: study rationale and methodology
Sickle cell disease (SCD) is a common condition within sub-Saharan Africa and associated with high under-5 mortality (U5M). The American Society of Hematology instituted the Consortium on Newborn Screening in Africa (CONSA) for SCD, a 7-country network of sites to implement standardized newborn hemoglobinopathy screening and early intervention for children with SCD in sub-Saharan Africa. CONSA’s overall hypothesis is that early infant SCD screening and entry into standardized, continuous care will reduce U5M compared with historical estimates in the region. Primary trial objectives are to determine the population-based birth incidence of SCD and effectiveness of early standardized care for preventing early mortality consortium-wide at each country’s site(s). Secondary objectives are to establish universal screening and early interventions for SCD within clinical networks of CONSA partners and assess trial implementation. Outcomes will be evaluated from data collected using a shared patient registry. Standardized trial procedures will be implemented among designated birth populations in 7 African countries whose programs met eligibility criteria. Treatment protocol includes administering antibacterial and antimalarial prophylaxis and standard childhood vaccinations against infections commonly affecting children with SCD. Infants with a positive screen and confirmation of SCD within the catchment areas defined by each consortium partner will be enrolled in the clinical intervention protocol and followed regularly until age of 5 years. Effectiveness of these early interventions, along with culturally appropriate family education and counseling, will be evaluated by comparing U5M in the enrolled cohort to estimated preprogram data. Here, we describe the methodology planned for this trial.
- 27 October 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (24) , 6187-6197
Open AccessThe Consortium on Newborn Screening in Africa for sickle cell disease: study rationale and methodology
Sickle cell disease (SCD) is a common condition within sub-Saharan Africa and associated with high under-5 mortality (U5M). The American Society of Hematology instituted the Consortium on Newborn Screening in Africa (CONSA) for SCD, a 7-country network of sites to implement standardized newborn hemoglobinopathy screening and early intervention for children with SCD in sub-Saharan Africa. CONSA’s overall hypothesis is that early infant SCD screening and entry into standardized, continuous care will reduce U5M compared with historical estimates in the region. Primary trial objectives are to determine the population-based birth incidence of SCD and effectiveness of early standardized care for preventing early mortality consortium-wide at each country’s site(s). Secondary objectives are to establish universal screening and early interventions for SCD within clinical networks of CONSA partners and assess trial implementation. Outcomes will be evaluated from data collected using a shared patient registry. Standardized trial procedures will be implemented among designated birth populations in 7 African countries whose programs met eligibility criteria. Treatment protocol includes administering antibacterial and antimalarial prophylaxis and standard childhood vaccinations against infections commonly affecting children with SCD. Infants with a positive screen and confirmation of SCD within the catchment areas defined by each consortium partner will be enrolled in the clinical intervention protocol and followed regularly until age of 5 years. Effectiveness of these early interventions, along with culturally appropriate family education and counseling, will be evaluated by comparing U5M in the enrolled cohort to estimated preprogram data. Here, we describe the methodology planned for this trial.
- Open Access
- 10 February 2020
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 20 (1) , 1-14
Healthy pregnancies and essential fats: focus group discussions with Zambian women on dietary need and acceptability of a novel RUSF containing fish oil DHA
Background: Nut butter-based Ready to Use Supplemental Foods (RUSF) are an effective way to add nutrients and calories to diets of malnourished and food insecure populations. The RUSF formulations have been further modified to add micronutrients including iron and folic acid needed during pregnancy and lactation. Because docosahexaenoic acid (DHA, C22:6 n-3) enhances fetal development and birth outcomes, it has been suggested that perhaps RUSF formulations for pregnancy should also include this Omega 3 fatty acid. The goal of the present study was to gain an understanding of Zambian women’s knowledge of nutritional needs in pregnancy through structured focus group discussions, and to formulate and determine the acceptability of a RUSF with DHA. Methods: Structured focus group sessions were conducted among women attending an antenatal clinic at the University Teaching Hospitals in Lusaka, Zambia. Dietary and nutrition knowledge was surveyed through structured dialogue that was recorded by audio and transcribed verbatim. An RUSF containing 400 mg DHA from fish oil in 50 g RUSF was designed and assessed for fatty acid content and product stability. Participants then sampled the RUSF-DHA, provided feedback on taste, and were surveyed about willingness to consume the novel formula using a standardized hedonic instrument. Results: The participants’ knowledge of foods recommended for use in pregnancy included fruits, vegetables, meat, and fish. Most women reported eating fish at least once per week, although the specific type of fish varied. Most did not have prior knowledge of the importance of consuming fish during pregnancy or that some fish types were more nutritional than others as they included omega 3 fatty acids. The participants were uniformly accepting of the RUSF-DHA for the purpose of enhancing birth and developmental outcomes, but were critical of the aroma in hedonic testing. Conclusions: Women were committed to consuming a healthy diet that would impact the outcome of pregnancy, and were receptive to advice on the importance of consuming foods such as fish as a source of DHA. The RUSF-DHA formulation was acceptable due to the potential benefits for the developing infant, however, the fishy odor may be limiting for long-term daily use.
- 10 February 2020
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 20 (1) , 1-14
Open AccessHealthy pregnancies and essential fats: focus group discussions with Zambian women on dietary need and acceptability of a novel RUSF containing fish oil DHA
Background: Nut butter-based Ready to Use Supplemental Foods (RUSF) are an effective way to add nutrients and calories to diets of malnourished and food insecure populations. The RUSF formulations have been further modified to add micronutrients including iron and folic acid needed during pregnancy and lactation. Because docosahexaenoic acid (DHA, C22:6 n-3) enhances fetal development and birth outcomes, it has been suggested that perhaps RUSF formulations for pregnancy should also include this Omega 3 fatty acid. The goal of the present study was to gain an understanding of Zambian women’s knowledge of nutritional needs in pregnancy through structured focus group discussions, and to formulate and determine the acceptability of a RUSF with DHA. Methods: Structured focus group sessions were conducted among women attending an antenatal clinic at the University Teaching Hospitals in Lusaka, Zambia. Dietary and nutrition knowledge was surveyed through structured dialogue that was recorded by audio and transcribed verbatim. An RUSF containing 400 mg DHA from fish oil in 50 g RUSF was designed and assessed for fatty acid content and product stability. Participants then sampled the RUSF-DHA, provided feedback on taste, and were surveyed about willingness to consume the novel formula using a standardized hedonic instrument. Results: The participants’ knowledge of foods recommended for use in pregnancy included fruits, vegetables, meat, and fish. Most women reported eating fish at least once per week, although the specific type of fish varied. Most did not have prior knowledge of the importance of consuming fish during pregnancy or that some fish types were more nutritional than others as they included omega 3 fatty acids. The participants were uniformly accepting of the RUSF-DHA for the purpose of enhancing birth and developmental outcomes, but were critical of the aroma in hedonic testing. Conclusions: Women were committed to consuming a healthy diet that would impact the outcome of pregnancy, and were receptive to advice on the importance of consuming foods such as fish as a source of DHA. The RUSF-DHA formulation was acceptable due to the potential benefits for the developing infant, however, the fishy odor may be limiting for long-term daily use.